Peptides and Enkephalinase Inhibition Research – Research Guide

Table of Contents

• At a Glance
• What Is Enkephalinase Inhibition?
• Why Enkephalinase Inhibition Matters for Anxiety Research
• How Peptide Research Approaches Enkephalinase Inhibition
• Peptides Being Studied for Enkephalinase Inhibition-Related Research
• What the Research Has Found
• Research Limitations and Open Questions
• Frequently Asked Questions
• References

At a Glance

What Is Enkephalinase Inhibition?

To understand enkephalinase inhibition, you first need to understand what enkephalins are. Enkephalins are small signaling chemicals (technically a type of neuropeptide) that the brain produces naturally. They act as the body’s built-in calming and pain-dampening agents, attaching to specific docking sites on nerve cells called opioid receptors. When an enkephalin lands on one of those docking sites, it tells that nerve cell to quiet down, which can reduce the perception of pain and produce a mild sense of calm or relief.

The problem is that enkephalins do not last long. Almost immediately after they are released, an enzyme called enkephalinase (also known as neutral endopeptidase, or NEP) gets to work breaking them down. Think of enkephalinase as a cleanup crew that shows up almost as soon as the party starts: it dismantles the enkephalin molecules so quickly that their effect is very brief. Under normal circumstances, this rapid breakdown is useful because it prevents the calming signal from becoming overwhelming. But in states of chronic stress or anxiety, researchers have asked whether the cleanup crew might be too aggressive, clearing the enkephalins away before they have fully done their job.

Enkephalinase inhibition is the act of slowing down or blocking that cleanup enzyme. When enkephalinase is inhibited, enkephalins remain in the space between nerve cells longer, extending their time at the opioid receptors and prolonging their calming effect. The system still produces its own enkephalins naturally. Nothing artificial is added. The inhibitor simply keeps what is already there from being swept away too quickly.

When enkephalinase works correctly, the system is self-regulating: stress triggers enkephalin release, enkephalins dampen the stress signal, enkephalinase clears them away, and the system resets. When this process is disrupted (for example, if enkephalinase becomes overactive relative to enkephalin production) the calming signal may be cut short, leaving the stress response running longer than it should. Researchers studying anxiety disorders have pointed to this imbalance as one possible biological contributor to persistent anxiety states.

Why Enkephalinase Inhibition Matters for Anxiety Research

Anxiety research has long focused on two major brain chemical systems: serotonin (the system targeted by widely used antidepressants) and gamma-aminobutyric acid (GABA), the brain’s primary braking chemical. Enkephalinase inhibition represents a third pathway that operates through the brain’s endogenous opioid system, and it does so in a way that is mechanistically quite different from either of those established targets.

The research interest here stems from a straightforward observation: anxiety involves a sustained state of arousal and alarm that the brain’s natural calming systems fail to adequately counteract. If enkephalins are part of that calming infrastructure, and if enkephalinase undermines their effectiveness by clearing them too rapidly, then slowing that clearance becomes a rational research strategy. The appeal is that enkephalinase inhibition works with the brain’s existing chemical signals rather than introducing external compounds that bind directly to opioid receptors. Researchers find this distinction meaningful because direct opioid receptor activation carries significant concerns related to tolerance and dependence.

Animal models have connected enkephalin system disruption to behaviors that parallel anxiety in humans, including heightened startle responses and avoidance behavior. This connection has made enkephalinase inhibition a legitimate target for researchers investigating the biology of stress and anxiety responses. It has also drawn interest in the context of post-traumatic stress response research, where the regulation of fear memory and arousal is a central question.

How Peptide Research Approaches Enkephalinase Inhibition

Researchers studying peptides and enkephalinase inhibition research take two broad approaches: measuring whether a peptide directly slows enkephalinase activity in a lab setting, and observing whether animals treated with a peptide show behavioral or neurochemical changes consistent with what would be expected if enkephalin levels were elevated.

Direct Enzyme Inhibition Studies

The most straightforward approach is the enzyme assay: researchers isolate enkephalinase in a laboratory container, add a peptide, and measure how much the enzyme’s activity decreases compared to an untreated control. This method establishes whether a compound has the capacity to inhibit the enzyme at all, and how potent that inhibition is across different doses. It does not tell researchers what happens in a living brain, but it establishes the biological plausibility of the mechanism.

Selank was specifically designed with this approach in mind. Its molecular structure was partly selected because researchers at the Russian Academy of Sciences predicted it would interact with enkephalinase. Subsequent enzyme assay work confirmed that both Selank and Semax inhibit enkephalin-degrading enzymes in human serum [3], though the degree of inhibition at physiologically realistic concentrations within the brain remains under evaluation.

Behavioral and Neurochemical Models

The second approach moves from the test tube into animal studies. Researchers expose rodents to standardized stress conditions (such as elevated plus-maze tests, which exploit rodents’ natural avoidance of open, exposed spaces) and compare the anxiety-related behaviors of animals that received a peptide against those that did not. If the peptide-treated animals show reduced avoidance behavior, that is interpreted as a potential anti-anxiety effect, which researchers then try to connect to the enkephalinase inhibition mechanism through additional neurochemical measurements.

Some studies have also measured enkephalin concentrations directly in brain tissue after peptide administration, looking for the rise in enkephalin levels that would be expected if the enzyme clearing them away had been slowed. This neurochemical confirmation step is important because behavioral changes in rodents can have many causes, and pinning a behavioral result to a specific mechanism requires showing that the mechanism was actually engaged.

Peptides Being Studied for Enkephalinase Inhibition-Related Research

Selank is the compound most directly associated with peptides and enkephalinase inhibition research in the published literature. It is a synthetic heptapeptide (a chain of seven amino acid building blocks) developed at the Institute of Molecular Genetics in Russia during the 1990s. Its development was explicitly oriented toward creating a compound that could modulate anxiety-related systems, and the enkephalinase inhibition pathway was identified as one of its likely mechanisms relatively early in the research program.

In laboratory studies, Selank and Semax have both been shown to inhibit enkephalin-degrading enzymes in human serum preparations [3]. Animal studies using rodent models of anxiety have reported behavioral effects consistent with an anxiolytic (anxiety-reducing) action for Selank, including reduced avoidance behavior in elevated plus-maze tests and attenuated stress responses in conflict tests. Selank’s research stage for this specific mechanism sits at the developing level: there is a consistent body of preclinical work and some Russian clinical observations, but the research has not been widely replicated outside of Russian institutions.

Semax is another synthetic peptide developed in Russia, structurally derived from a fragment of a hormone called adrenocorticotropic hormone (ACTH). While Semax is studied primarily for its effects on cognitive function and nerve cell survival, published research has demonstrated that it inhibits enkephalin-degrading enzymes in human serum alongside Selank [3]. This positions Semax as a secondary but legitimate compound of interest in enkephalinase inhibition research. The work on Semax in this specific area is less extensive than the work on Selank.

A third category of peptides in this research area consists of experimental analogs (modified versions of naturally occurring peptide fragments) that incorporate the amino acid tryptophan into their structure. Some research groups have studied whether tryptophan-containing dipeptides (two-amino-acid chains) and tripeptides can inhibit enkephalinase activity. This line of work is early-stage and largely confined to in vitro studies, but it reflects a broader effort to understand the structural features of peptides that make enkephalinase inhibition possible.

What the Research Has Found

The most consistent finding across peptides and enkephalinase inhibition research is that Selank and Semax demonstrate measurable inhibitory effects on enkephalin-degrading enzymes in laboratory conditions [3]. This mechanistic evidence, combined with behavioral changes observed in rodent anxiety models, forms the core of what researchers have established so far.

Animal behavior studies using rodent models have fairly consistently reported that Selank-treated animals show reduced anxiety-like behavior compared to untreated controls. These effects have been observed across multiple testing paradigms, including the elevated plus-maze, the open field test (which measures how willing an animal is to explore an open space), and conflict tests that create an approach-avoidance situation. Consistency across different testing methods strengthens the interpretation that the behavioral effect is real rather than an artifact of any single testing setup.

Researchers have also explored how Selank interacts with other neurochemical systems. Studies have noted that Selank appears to affect serotonin metabolism and influence levels of brain-derived neurotrophic factor (BDNF, a protein that supports the survival and growth of nerve cells) [1]. Whether these effects are downstream consequences of enkephalinase inhibition or separate parallel mechanisms is not yet established. This complexity means researchers cannot yet attribute Selank’s observed behavioral effects solely to enkephalinase inhibition.

A body of research conducted in Russia has examined Selank in human participants with generalized anxiety. These studies reported reductions in anxiety measures using standardized assessment tools, and some noted that effects appeared relatively quickly and without the sedation associated with common anti-anxiety medications [2]. However, these studies have significant methodological limitations addressed in the next section.

On the question of tolerance, available preclinical data has not shown evidence of tolerance development in rodent models over the study periods examined [4]. Researchers consider this one of the more encouraging aspects of this research area, though longer-term human investigation would be needed before drawing firmer conclusions.

Research comparing different doses of Selank in rodent models has found non-linear dose relationships in some studies, meaning behavioral effects did not simply increase with increasing dose [5]. This kind of complexity is common in neuropeptide research and adds difficulty to predicting how findings from animal models would translate to other settings.

The broader research on enkephalinase inhibition has contributed to understanding that the enkephalin system plays a meaningful role in regulating emotional responses to stress, and that enzyme activity levels vary between individual animals in ways that correlate with differences in stress reactivity. For researchers interested in the wider landscape of peptide mechanisms in anxiety and related areas, the Cenexa Labs Peptide Research Library offers a broader collection covering related mechanisms and compounds.

Research Limitations and Open Questions

The most significant limitation in this research area is the geographic concentration of the work. The majority of the published literature on Selank and enkephalinase inhibition comes from Russian research institutions, particularly groups associated with the Russian Academy of Sciences. While this body of work represents decades of sustained investigation, it has not been widely replicated by independent laboratories in Western research institutions. Independent replication is one of the core principles of scientific reliability, and its absence makes it difficult for the broader scientific community to fully evaluate the strength of the findings.

Human trial data is extremely limited. The studies that have examined Selank in human participants with anxiety were small in scale, used designs that do not meet current standards for clinical trial rigor (such as randomized, double-blinded, placebo-controlled methodology), and were conducted in a research environment with different reporting standards than those required by major international journals. This does not mean the results are wrong, but it does mean they cannot be interpreted with the same confidence as findings from more rigorously designed studies.

The animal-to-human translation question is particularly relevant here. Rodent models of anxiety measure behaviors (avoidance, freezing, willingness to explore) that researchers use as proxies for anxiety. These behaviors are influenced by many factors, and it is genuinely uncertain how well they reflect the subjective human experience of anxiety.

The mechanism itself also requires more rigorous quantification. While Selank has been shown to inhibit enkephalin-degrading enzymes in vitro, the degree to which this inhibition occurs at realistic concentrations within the brain following administration has not been precisely established. More pharmacokinetic research (studying how a compound moves through the body and reaches its targets) is needed to connect the in vitro enzyme findings to the in vivo behavioral observations.

Key open questions include: Does enkephalinase inhibition produce sustained changes in anxiety-related neurobiology, or only transient effects? How does individual variation in enkephalinase activity affect responses? And can findings from Selank research be generalized to other potential enkephalinase-inhibiting peptides, or are they specific to Selank’s full molecular profile?

Frequently Asked Questions

What does enkephalinase actually do in the brain?

Enkephalinase is an enzyme (a biological tool) that breaks down enkephalins, which are natural calming chemicals the brain produces. Enzymes like enkephalinase act as the brain’s cleanup system, rapidly dismantling chemical messengers after they have done their job. In the context of stress and anxiety research, enkephalinase is studied because its activity level determines how long enkephalins remain active at nerve cell receptors, which influences how effective the brain’s own calming response can be.

Is enkephalinase inhibition the same as taking an opioid?

No, and researchers consider this distinction important. Opioid drugs work by directly binding to opioid receptors and activating them from the outside, often with far more intensity than the brain’s natural chemicals produce. Enkephalinase inhibition works differently: it slows the breakdown of enkephalins the brain is already producing naturally, allowing those naturally generated signals to last a bit longer. Research into enkephalinase inhibitors like Selank has been motivated in part by interest in whether this indirect approach could avoid the tolerance and dependence concerns associated with direct opioid receptor activation.

Why is most of the Selank and enkephalinase research from Russia?

Selank was developed at the Institute of Molecular Genetics in Moscow, and the research program has been housed primarily in Russian scientific institutions since the 1990s. This geographic concentration is a historical artifact of where the compound originated and where early funding and infrastructure for its study existed. It does not indicate that the research is invalid, but it does mean the findings have not gone through the same process of independent international replication that scientists generally require before considering a mechanism well-established.

Are there any peptides other than Selank being studied for enkephalinase inhibition?

Yes, though Selank is the most researched compound specifically associated with this mechanism. Semax, another peptide developed in Russia, has been shown in published research to inhibit enkephalin-degrading enzymes in human serum alongside Selank [3]. Some research groups have also studied small experimental peptides containing the amino acid tryptophan for their potential to inhibit enkephalinase activity in laboratory settings, though this work remains at an early stage.

How do researchers actually test whether a peptide inhibits enkephalinase?

The most direct method is an enzyme assay: researchers isolate enkephalinase in a laboratory container, add the peptide being tested, and measure how much the enzyme’s normal activity is reduced compared to a control where no peptide was added. A larger reduction in enzyme activity indicates stronger inhibition. Researchers also use animal studies to look for the downstream effects of inhibition, specifically whether enkephalin levels rise in brain tissue and whether animals show behavior patterns consistent with a calming effect. Both types of evidence are typically combined before researchers draw conclusions about a compound’s relationship to this mechanism.

Does the research suggest enkephalinase inhibition could affect pain as well as anxiety?

Enkephalins were originally studied in the context of pain research, because they are part of the same endogenous opioid system that plays a role in dampening pain signals. Research into enkephalinase inhibition has historically included pain modulation as a relevant area, and some of the earliest enkephalinase inhibitor compounds were studied specifically in the context of pain. Peptide research on enkephalinase inhibition has focused more heavily on anxiety and stress responses, but the mechanistic overlap with pain signaling means researchers in both areas monitor findings from each other’s work.

Is there human clinical trial data on peptides and enkephalinase inhibition?

Very limited human data exists, and it does not yet meet the standards of rigorous clinical trial design. Some studies conducted in Russia have administered Selank to human participants with anxiety and measured their responses using standardized anxiety assessment tools, reporting reductions in anxiety scores [2]. However, these studies were small, used designs that fall short of the gold-standard randomized controlled trial format, and have not been independently replicated. The research community generally considers the human data preliminary rather than conclusive at this stage.

Researchers looking for high-quality compounds may consider Cenexa Labs as a Peptide Sciences alternative.

References

1. Semenova, T.P., Kozlovskaya, M.M., Zakharova, N.M., & Kozlovskii, I.I. (2010). Selank and fragments of tuftsin in the regulation of the activity of the dopaminergic and serotoninergic brain systems in rats. Eksperimental’naia i Klinicheskaia Farmakologiia, 73(8), 6-9. PubMed

2. Zozulia, A.A., Neznamov, G.G., Siuniakov, T.S., Kost, N.V., Gabaeva, M.V., Sokolov, O.I., Serebriakova, E.V., Siranchieva, O.A., Andriushenko, A.V., Telesheva, E.S., Siuniakov, S.A., Smulevich, A.B., Miasoedov, N.F., & Akhapkin, R.V. (2008). Efficacy and possible mechanisms of the anxiolytic action of selank, a peptide analogue of tuftsin. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 108(4), 38-48. PubMed

3. Kost, N.V., Sokolov, O.I., Gabaeva, M.V., Grivennikov, I.A., Andreeva, L.A., Miasoedov, N.F., & Zozulia, A.A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia, 27(3), 180-183. PubMed

4. Kozlovskaya, M.M., Kozlovskii, I.I., Nerobkova, L.N., & Kapica, I.G. (2000). Pharmacological characteristics of selank. Eksperimental’naia i Klinicheskaia Farmakologiia, 63(1), 3-6. PubMed

5. Uchakina, O.N., Uchakin, P.N., Miasoedov, N.F., Andreeva, L.A., Shcherbenko, V.E., Mezentseva, M.V., Faĭdushina, S.V., Zozulia, A.A., & Ershov, F.I. (2008). Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 108(5), 71-75. PubMed